These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23629473)

  • 1. Targeted therapies: HER2-positive breast cancer-sifting through many good options.
    Krop IE
    Nat Rev Clin Oncol; 2013 Jun; 10(6):312-3. PubMed ID: 23629473
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to F. Ades.
    Guan Z
    J Clin Oncol; 2013 Nov; 31(33):4272. PubMed ID: 24127453
    [No Abstract]   [Full Text] [Related]  

  • 3. Lapatinib versus placebo added to paclitaxel in first-line human epidermal growth factor receptor 2-positive metastatic breast cancer: ethical lessons not learned from Africa.
    Ades F
    J Clin Oncol; 2013 Nov; 31(33):4271. PubMed ID: 24127451
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
    J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Of mice and (wo)men: is this any way to test a new drug?
    Haddad TC; Yee D
    J Clin Oncol; 2008 Feb; 26(6):830-2. PubMed ID: 18281652
    [No Abstract]   [Full Text] [Related]  

  • 7. [Novel target therapies used in breast cancer management].
    Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
    Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better treatments needed for breast cancer brain metastases.
    Lin NU
    Lancet Oncol; 2015 Dec; 16(16):1583-4. PubMed ID: 26596673
    [No Abstract]   [Full Text] [Related]  

  • 10. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 11. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials.
    Xu ZQ; Zhang Y; Li N; Liu PJ; Gao L; Gao X; Tie XJ
    BMJ Open; 2017 Mar; 7(3):e013053. PubMed ID: 28289045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Colomer R; Brunet J; Menendez JA
    Ann Oncol; 2008 Jun; 19(6):1097-109. PubMed ID: 18283037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin?
    Loibl S
    JAMA Oncol; 2015 Jul; 1(4):455-6. PubMed ID: 26181253
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.
    Castañeda CA; Gomez HL
    Nat Rev Clin Oncol; 2009 Jun; 6(6):308-9. PubMed ID: 19483734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy.
    Zoeller JJ; Press MF; Selfors LM; Dering J; Slamon DJ; Hurvitz SA; Brugge JS
    PLoS One; 2021; 16(5):e0251163. PubMed ID: 33951110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy for metastatic breast cancer.
    Muss HB
    N Engl J Med; 2006 Dec; 355(26):2783-5. PubMed ID: 17192546
    [No Abstract]   [Full Text] [Related]  

  • 20. HER2-positive breast cancer: Current and new therapeutic strategies.
    Escrivá-de-Romaní S; Arumí M; Bellet M; Saura C
    Breast; 2018 Jun; 39():80-88. PubMed ID: 29631097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.